Shelley Coleman
- Oncology top 0.5%
- Pulmonary and Respiratory Medicine top 1%
- Immunology top 5%
- Molecular Biology
- Cancer Research top 5%
- Co-authors
- Anthony LeeMark A. SocinskiMartin ReckFrancesco OrlandiNaoyuki NogamiDenis Moro‐SibilotFabrice BarlésiDaniil Stroyakovskiy
- Topics
- Cancer Immunotherapy and Biomarkers (9 papers)Lung Cancer Treatments and Mutations (6 papers)Colorectal Cancer Treatments and Studies (4 papers)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Shelley Coleman
10 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Oncology 2.8k
- Pulmonary and Respiratory Medicine 1.9k
- Immunology 599
- Molecular Biology 399
- Cancer Research 387
Countries citing papers authored by Shelley Coleman
This map shows the geographic impact of Shelley Coleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shelley Coleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shelley Coleman more than expected).
Fields of papers citing papers by Shelley Coleman
This network shows the impact of papers produced by Shelley Coleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shelley Coleman. The network helps show where Shelley Coleman may publish in the future.
Co-authorship network of co-authors of Shelley Coleman
This figure shows the co-authorship network connecting the top 25 collaborators of Shelley Coleman. A scholar is included among the top collaborators of Shelley Coleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shelley Coleman. Shelley Coleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCbreakdown → | 316 |
| 2 | 30 | |
| 3 | 56 | |
| 4 | 50 | |
| 5 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCbreakdown → | 2635 |
| 6 | 68 | |
| 7 | 13 | |
| 8 | 1 | |
| 9 | 4 | |
| 10 | 2 |
About Shelley Coleman
Shelley Coleman is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 10 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). The work is most often cited by research in Oncology (2.8k citations), Pulmonary and Respiratory Medicine (1.9k citations) and Immunology (599 citations). Shelley Coleman has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Anthony Lee, Mark A. Socinski, Martin Reck, Francesco Orlandi, Naoyuki Nogami, Denis Moro‐Sibilot, Fabrice Barlési, Daniil Stroyakovskiy, Federico Cappuzzo and Gene Grant Finley. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.